In Brief: Ela Medical
This article was originally published in The Gray Sheet
Executive Summary
Ela Medical: Montrouge, France-based subsidiary of Synthelabo's Biomedical division commences European roll-out of ventricular models of its Stelid family of steroid-eluding pacing leads. The devices incorporate a steroid collar technology that allows for release during the initial days after implantation of the anti-inflammatory drug dexamethasone, and a micro porous carbon electrode. Atrial models of the Stelid devices are undergoing clinical evaluation and are slated for European launch by the end of the year. Separately, Ela reports the European introduction of its Defender II 75 cc dual-chamber defibrillator. The device features the company's Parad algorithm, which allows for collection of both atrial and ventricular data...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.